About Aevi Genomic Medicine
Aevi Genomic Medicine is a company based in Wayne (United States) founded in 2001 was acquired by Cerecor in December 2019.. Aevi Genomic Medicine has raised $28.43 million across 12 funding rounds from investors including Children's Hospital of Philadelphia, Cerecor and Alta Partners. The company has 3 employees as of September 30, 2021. Aevi Genomic Medicine operates in a competitive market with competitors including Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others.
- Headquarter Wayne, United States
- Employees 3 as on 30 Sep, 2021
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aevi Genomic Medicine, Inc.
-
Annual Revenue
-
Net Profit
$-30.78 M11as on Dec 31, 2018
-
EBITDA
$-30.96 M11as on Dec 31, 2018
-
Total Equity Funding
$28.43 M (USD)
in 12 rounds
-
Latest Funding Round
$28 M (USD), Post-IPO
Aug 10, 2017
-
Investors
Children's Hospital of Philadelphia
& 4 more
-
Employee Count
3
as on Sep 30, 2021
-
Acquired by
Cerecor
(Dec 05, 2019)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Aevi Genomic Medicine
Aevi Genomic Medicine has successfully raised a total of $28.43M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in August 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 12
- Last Round Post-IPO — $28.0M
-
First Round
First Round
(22 Jun 2001)
- Investors Count 4
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2017 | Amount | Post-IPO - Aevi Genomic Medicine | Valuation |
investors |
|
| Oct, 2015 | Amount | Post-IPO - Aevi Genomic Medicine | Valuation |
investors |
|
| Jun, 2015 | Amount | Grant - Aevi Genomic Medicine | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aevi Genomic Medicine
Aevi Genomic Medicine has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Children's Hospital of Philadelphia, Cerecor and Alta Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare companies
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location | |
|
VC firm investing in Western Europe, the US and Israel
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aevi Genomic Medicine
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aevi Genomic Medicine
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aevi Genomic Medicine Comparisons
Competitors of Aevi Genomic Medicine
Aevi Genomic Medicine operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, BeiGene, Spark Therapeutics and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aevi Genomic Medicine
Frequently Asked Questions about Aevi Genomic Medicine
When was Aevi Genomic Medicine founded?
Aevi Genomic Medicine was founded in 2001.
Where is Aevi Genomic Medicine located?
Aevi Genomic Medicine is headquartered in Wayne, United States.
Who is the current CEO of Aevi Genomic Medicine?
Mike Cola is the current CEO of Aevi Genomic Medicine.
Is Aevi Genomic Medicine a funded company?
Aevi Genomic Medicine is a funded company, having raised a total of $28.43M across 12 funding rounds to date. The company's 1st funding round was a Grant of $3.4M, raised on Jun 22, 2001.
How many employees does Aevi Genomic Medicine have?
As of Sep 30, 2021, the latest employee count at Aevi Genomic Medicine is 3.
What does Aevi Genomic Medicine do?
Aevi Genomic Medicine was founded in 2001 and is based in Wayne, United States. Operations center on the creation of treatments for pediatric-onset rare diseases, with emphasis on neurology and hematology sectors. The pipeline encompasses AEVI-001, a small molecule addressing metabotropic glutamate receptor mutations for ADHD and 22q deletion syndrome in Phase 1 and 2 trials, alongside AEVI-002, an anti-LIGHT monoclonal antibody for inflammatory bowel disease in Phase 1.
Who are the top competitors of Aevi Genomic Medicine?
Aevi Genomic Medicine's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Who are Aevi Genomic Medicine's investors?
Aevi Genomic Medicine has 5 investors. Key investors include Children's Hospital of Philadelphia, Cerecor, Alta Partners, Koor Industries, and Alta Berkeley.